VENCLEXTA

VENCLEXTA (Venetoclax)

VENCLEXTA

Venetoclax

10 mg, 50 mg and 100 mg tablets.

ABBVIE INC.

Medical Use

Venclexta, which contains the active ingredient Venetoclax, is a BCL-2 inhibitor used for:

  • -Treating chronic lymphocytic leukemia (CLL).
  • -Managing small lymphocytic lymphoma (SLL), with or without 17p deletion, in patients who have previously undergone at least one therapy.
  • -In combination with azacitidine, decitabine, or low-dose cytarabine, for treating newly-diagnosed acute myeloid leukemia (AML) in adults aged 75 years or older, or those with comorbidities that prevent the use of intensive induction chemotherapy.